{
    "nct_id": "NCT06113471",
    "official_title": "A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo",
    "inclusion_criteria": "* Aged ≥ 18 years.\n* Clinical diagnosis of nonsegmental vitiligo and meet the following:\n\n  * T-BSA ≥ 5%\n  * T-VASI score ≥ 4\n  * F-BSA ≥ 0.5%\n  * F-VASI score ≥ 0.5\n* Agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit.\n* Willingness to avoid pregnancy or fathering children.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Other forms of vitiligo or skin depigmentation disorders.\n* Clinically significant abnormal TSH or free T4 at screening.\n* Use of laser or phototherapy within 8 weeks and dihydroxyacetone within 4 weeks prior to Day 1.\n* Current or past use of the depigmenting agent monobenzyl ether of hydroquinone including Benoquin®.\n* History of melanocyte-keratinocyte transplantation procedure or other surgical treatment for vitiligo.\n* Spontaneous and significant repigmentation within 6 months prior to screening.\n* Women who are pregnant, considering pregnancy, or breast feeding.\n* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or recurrent dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies.\n* Evidence of infection with TB, HBV, HCV or HIV.\n* History of failure to JAK inhibitor treatment of any inflammatory disease.\n* Laboratory values outside of the protocol-defined ranges.\n\nOther protocol-defined Inclusion/Exclusion Criteria may apply.",
    "miscellaneous_criteria": ""
}